KR960705585A - 경비조성물 및 그것을 함유하는 경비제제(pernasal composition and pernasal preparation containing the saem) - Google Patents

경비조성물 및 그것을 함유하는 경비제제(pernasal composition and pernasal preparation containing the saem) Download PDF

Info

Publication number
KR960705585A
KR960705585A KR1019960702035A KR19960702035A KR960705585A KR 960705585 A KR960705585 A KR 960705585A KR 1019960702035 A KR1019960702035 A KR 1019960702035A KR 19960702035 A KR19960702035 A KR 19960702035A KR 960705585 A KR960705585 A KR 960705585A
Authority
KR
South Korea
Prior art keywords
composition
pernasal
active substance
alcohol
pharmacologically active
Prior art date
Application number
KR1019960702035A
Other languages
English (en)
Other versions
KR100217258B1 (ko
Inventor
카쯔야 무카에
미쯔히로 미즈마치
코오키 이토
Original Assignee
나까토미 히로타카
히사미쯔세이야꾸 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나까토미 히로타카, 히사미쯔세이야꾸 가부시기가이샤 filed Critical 나까토미 히로타카
Publication of KR960705585A publication Critical patent/KR960705585A/ko
Application granted granted Critical
Publication of KR100217258B1 publication Critical patent/KR100217258B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

본 발명은 약리활성물질과 물과 알콜류를 함유하고, 이 알콜류의 함량이 조성물전체량의 10~70용량%인 것을 특징으로 하는 경비조성물 및 그 조성물을 함유해서 이루어진 경비제제이다. 상기 경비조성물은, 매우 안전성이 높고, 또한 신속한 약물흡수와 함께 장시간에 걸친 약물혈중농도의 유지를 가능하게 하므로서, 상기 조성물 및 그것을 함유해서 이루어진 경비 제제를 사용하면 종래경비투여가 곤란하였던 약물의 경비투여가 가능하게 되고, 또한 충분한 약호를 기대할 수 있게 된다.

Description

경비조성물 및 그것을 함유하는 경비제제(PERNASAL COMPOSITION AND PERNASAL PREPARATION CONTAINING THE SAEM)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 약물로서 TRH-T를 사용, 쥐를 실험동물로서 실시한 경우에 있어서의 TRH-T의 혈장중농도의 결과를 표시한 도면, 제2도는 약물로서 TRH-T를 사용, 쥐를 실험동물로서 실시한 경우에 있어서의 TRH-T의 혈장중농도의 결과를 표시한 도면, 제3도는 토끼의 비점막으로부터 얻은 효소액을 사용해서 실시한 분해효소저해성 평가시험의 결과를 표시한 도면.

Claims (7)

  1. 약리활성 물질과 물의 알코류를 함유하고, 이 알콜류의 함량이 조성물 전체량의 10~70용량%인 것을 특징으로 하는 경비조성물.
  2. 제1항에 있어서, 상기 알콜류가 탄소수 1~4의 저급알콜, 탄소수 2~5의 저급알칸디올 또는 탄소수 3~6의 저급알칸트리올인 것을 특징으로 하는 경비조성물.
  3. 제2항에 있어서, 상기 알콜류가 프로필렌글리콜인 것을 특징으로 하는 경비조성물.
  4. 제3항에 있어서, 상기 프로필렌글리콜의 함량이 조성물 전체량의 15~30용량%인 것을 특징으로 하는 경비조성물.
  5. 제1항~4항의 어느 한 항에 있어서, 상기 약리활성물질이 생리활성펩티드, 생리활성단백, 이들의 염. 이들의 유도체, 이들의 이성체, 이들의 광학이성체 또는 그들의 혼합물인 것을 특징으로 하는 경비조성물.
  6. 제5항에 있어서, 상기 약리활성물질이 생리활성펩티드인 프로틸레린(TRH), 그 염, 그 유도체, 그 이성체, 그 광학이성체 또는그들의 혼합물인 것을 특징으로 하는 경비조성물.
  7. 청구범위 제1항~제6항 중 어느 항에 기재된 조성물을 함유해서 이루어진 것을 특징으로 하는 경비제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702035A 1993-10-21 1994-10-19 경비조성물 KR100217258B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP93-287784 1993-10-21
JP28778493 1993-10-21
PCT/JP1994/001762 WO1995011042A1 (fr) 1993-10-21 1994-10-19 Composition administree par voie nasale et preparation contenant celle-ci

Publications (2)

Publication Number Publication Date
KR960705585A true KR960705585A (ko) 1996-11-08
KR100217258B1 KR100217258B1 (ko) 1999-09-01

Family

ID=17721701

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702035A KR100217258B1 (ko) 1993-10-21 1994-10-19 경비조성물

Country Status (11)

Country Link
US (1) US5789375A (ko)
EP (1) EP0724885B1 (ko)
KR (1) KR100217258B1 (ko)
CN (1) CN1098708C (ko)
AT (1) ATE214289T1 (ko)
AU (1) AU681452B2 (ko)
CA (1) CA2174324A1 (ko)
DE (1) DE69430132T2 (ko)
DK (1) DK0724885T3 (ko)
ES (1) ES2171469T3 (ko)
WO (1) WO1995011042A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970032844A (ko) * 1995-12-29 1997-07-22 김준웅 지속성 경비투여제제
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69928563T2 (de) * 1998-12-09 2006-07-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
JP3498041B2 (ja) 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
WO2004108161A1 (ja) * 2003-06-06 2004-12-16 Takeda Pharmaceutical Company Limited 固形製剤
EP2484687A3 (en) 2003-08-08 2012-11-14 Life Technologies Corporation Methods and compositions for seamless cloning of nucleic acid molecules
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP2457580A1 (en) * 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8440631B2 (en) * 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57188526A (en) * 1981-05-14 1982-11-19 Takeda Chem Ind Ltd Peptide-containing pharmaceutical preparation
JPS60224638A (ja) * 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
JPH0643390B2 (ja) * 1986-04-08 1994-06-08 久光製薬株式会社 アザシクロアルカン誘導体
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
JPH01160916A (ja) * 1987-12-18 1989-06-23 Tanabe Seiyaku Co Ltd ドーパミン経鼻投与製剤
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols

Also Published As

Publication number Publication date
ES2171469T3 (es) 2002-09-16
ATE214289T1 (de) 2002-03-15
DE69430132D1 (de) 2002-04-18
EP0724885A4 (en) 1997-06-25
AU7949294A (en) 1995-05-08
WO1995011042A1 (fr) 1995-04-27
AU681452B2 (en) 1997-08-28
US5789375A (en) 1998-08-04
DE69430132T2 (de) 2002-08-29
CN1098708C (zh) 2003-01-15
KR100217258B1 (ko) 1999-09-01
CN1133565A (zh) 1996-10-16
DK0724885T3 (da) 2002-05-21
CA2174324A1 (en) 1995-04-27
EP0724885B1 (en) 2002-03-13
EP0724885A1 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
KR960705585A (ko) 경비조성물 및 그것을 함유하는 경비제제(pernasal composition and pernasal preparation containing the saem)
KR100368181B1 (ko) 시각조직에의국부도포를위한누선특효유제
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
US4153689A (en) Stable insulin preparation for nasal administration
CA2292673C (en) Pharmaceutical compositions containing eletriptan hemisulphate
KR920700679A (ko) 비(nasal) 전달용 지질부형제와 그 사용법
Hermens et al. The influence of drugs on nasal ciliary movement
KR890700036A (ko) 비내 투여용 제제 및 그 제조방법
KR960705556A (ko) 비타민 k를 사용하여 피부의 혈관 질환을 처치하는 방법 및 조성물(composition and method for treating blood vessel disorders of the skin using vitamin k)
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
AU2460292A (en) Improved transdermal formulations
ATE191719T1 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
PT758231E (pt) Composicoes farmaceuticas a base de derivados da classe dos taxanos
KR970025615A (ko) 암 전이 억제제
AR017973A1 (es) Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo
KR900015749A (ko) 인터루킨-1제형
Lee et al. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats
KR930702965A (ko) 생체이용성이 개선된 프로부콜 함유 제약 조성물
KR920003981A (ko) 항염증성 조성물
KR100466757B1 (ko) 생체에 펩티드성 약물을 유입시키기 위한 국소 제제
Holdeman et al. Effects of massive doses of α-MSH on thermoregulation in the rabbit
HU226374B1 (en) Pharmaceutical combination of a bradykinin antagonist and an antiviral agent
JPS59176216A (ja) 有用なインタ−フエロン製剤
EA200700968A1 (ru) Фармацевтическая композиция для лечения сахарного диабета 2 типа
BRPI0416979A (pt) forma de apresentação transdérmica, lìquida ou semi-sólida, resistente a uv, com substáncia ativa fotossensìvel

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20060525

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee